See more : BP p.l.c. (BP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Frequency Therapeutics, Inc. (FREQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Frequency Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- AGBA Acquisition Limited (AGBA) Income Statement Analysis – Financial Results
- EQ Health Acquisition Corp. (EQHA-UN) Income Statement Analysis – Financial Results
- Skylight Health Group Inc. (SLHG.V) Income Statement Analysis – Financial Results
- Orbia Advance Corporation, S.A.B. de C.V. (ORBIA.MX) Income Statement Analysis – Financial Results
- Groupe Bruxelles Lambert SA (GBLBY) Income Statement Analysis – Financial Results
Frequency Therapeutics, Inc. (FREQ)
About Frequency Therapeutics, Inc.
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 49.42M | 60.92M | 37.42M | 18.78M | 11.88M | 11.97M |
| General & Administrative | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.58M | 37.18M | 27.12M | 30.84M | 7.06M | 4.34M |
| Other Expenses | 1.06M | -266.00K | 0.00 | 16.00M | 0.00 | 0.00 |
| Operating Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Cost & Expenses | 83.00M | 98.10M | 64.53M | 49.62M | 18.94M | 16.31M |
| Interest Income | 1.33M | 397.00K | 994.00K | 1.78M | 0.00 | -174.00K |
| Interest Expense | 961.00K | 764.00K | 0.00 | 1.78M | 106.00K | 174.00K |
| Depreciation & Amortization | 2.38M | 2.91M | -80.00K | -145.00K | 654.00K | 531.00K |
| EBITDA | -80.62M | -81.13M | -27.55M | -20.68M | -18.29M | -12.02M |
| EBITDA Ratio | 0.00% | -576.66% | -74.71% | -71.92% | 0.00% | 0.00% |
| Operating Income | -83.00M | -84.03M | -27.55M | -20.68M | -18.94M | -16.31M |
| Operating Income Ratio | 0.00% | -597.32% | -74.49% | -71.42% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | -640.00K | 1.07M | 1.93M | -224.00K | -3.93M |
| Income Before Tax | -81.58M | -84.67M | -26.48M | -18.75M | -19.17M | -20.24M |
| Income Before Tax Ratio | 0.00% | -601.87% | -71.59% | -64.76% | 0.00% | 0.00% |
| Income Tax Expense | -2.00K | 15.00K | 35.00K | -2.74M | -118.00K | 3.93M |
| Net Income | -81.58M | -84.69M | -26.51M | -16.00M | -19.17M | -20.24M |
| Net Income Ratio | 0.00% | -601.98% | -71.68% | -55.29% | 0.00% | 0.00% |
| EPS | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| EPS Diluted | -2.33 | -2.47 | -0.82 | -1.85 | -1.59 | -1.68 |
| Weighted Avg Shares Out | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
| Weighted Avg Shares Out (Dil) | 35.08M | 34.35M | 32.25M | 8.65M | 12.06M | 12.06M |
FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ
New York, New York--(Newsfile Corp. - August 2, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive...
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - August 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) for violations of §§10(b)...
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - August 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeutics, Inc. ("Frequency" or "the Company") (NASDAQ: FREQ) for violations of §§10(b)...
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI
NEW YORK, NY / ACCESSWIRE / August 2, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the...
FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline Tomorrow in Securities Class Action - FREQ
New York, New York--(Newsfile Corp. - August 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive...
FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline Tomorrow in Securities Class Action - FREQ
New York, New York--(Newsfile Corp. - August 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive...
FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ
New York, New York--(Newsfile Corp. - July 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive...
FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ
New York, New York--(Newsfile Corp. - July 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021, inclusive...
FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc.
New York, New York--(Newsfile Corp. - July 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Frequency Therapeutics, Inc. ("Frequency Therapeutics") (NASDAQ: FREQ) between...
FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc.
New York, New York--(Newsfile Corp. - July 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Frequency Therapeutics, Inc. ("Frequency Therapeutics") (NASDAQ: FREQ) between...
Source: https://incomestatements.info
Category: Stock Reports